155 related articles for article (PubMed ID: 9202556)
21. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group.
Jardin A; Bensadoun H; Delauche-Cavallier MC; Stalla-Bourdillon A; Attali P
Br J Urol; 1994 Nov; 74(5):579-84. PubMed ID: 7530121
[TBL] [Abstract][Full Text] [Related]
22. Alfuzosin: a clinically uroselective alpha1-blocker.
Höfner K; Jonas U
World J Urol; 2002 Apr; 19(6):405-12. PubMed ID: 12022709
[TBL] [Abstract][Full Text] [Related]
23. The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Sánchez-Chapado M; Guil M; Badiella LI; Fernández-Hernando N; Alfaro V
BJU Int; 2000 Sep; 86(4):432-8. PubMed ID: 10971267
[TBL] [Abstract][Full Text] [Related]
24. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
Martorana G; Giberti C; Di Silverio F; von Heland M; Rigatti P; Colombo R; Casadei G; Pacifico P
Eur Urol; 1997; 32(1):47-53. PubMed ID: 9266231
[TBL] [Abstract][Full Text] [Related]
25. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.
McKeage K; Plosker GL
Drugs; 2002; 62(4):633-53. PubMed ID: 11893233
[TBL] [Abstract][Full Text] [Related]
26. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial.
Resnick MI; Roehrborn CG
Prostate Cancer Prostatic Dis; 2007; 10(2):155-9. PubMed ID: 17211442
[TBL] [Abstract][Full Text] [Related]
27. Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive medications.
Zhang LT; Lee SW; Park K; Chung WS; Kim SW; Hyun JS; Moon DG; Yang SK; Ryu JK; Yang DY; Moon KH; Min KS; Park JK
Clin Interv Aging; 2015; 10():277-86. PubMed ID: 25653511
[TBL] [Abstract][Full Text] [Related]
28. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
[TBL] [Abstract][Full Text] [Related]
29. Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia.
Lee M
Am J Health Syst Pharm; 2003 Jul; 60(14):1426-39. PubMed ID: 12892027
[TBL] [Abstract][Full Text] [Related]
30. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Höfner K; Claes H; De Reijke TM; Folkestad B; Speakman MJ
Eur Urol; 1999 Oct; 36(4):335-41. PubMed ID: 10473995
[TBL] [Abstract][Full Text] [Related]
31. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
de Reijke TM; Klarskov P
BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
[TBL] [Abstract][Full Text] [Related]
32. Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia.
Rosen R; Seftel A; Roehrborn CG
Int J Impot Res; 2007; 19(5):480-5. PubMed ID: 17717526
[TBL] [Abstract][Full Text] [Related]
33. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects.
MacDonald R; Wilt TJ
Urology; 2005 Oct; 66(4):780-8. PubMed ID: 16230138
[TBL] [Abstract][Full Text] [Related]
34. Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia.
Guay DR
Am J Geriatr Pharmacother; 2004 Mar; 2(1):14-23. PubMed ID: 15555475
[TBL] [Abstract][Full Text] [Related]
35. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
Lowe FC
Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of alfuzosin 10 mg once daily in the treatment of symptomatic benign prostatic hyperplasia.
Kuritzky L; Rosenberg MT; Sadovsky R
Int J Clin Pract; 2006 Mar; 60(3):351-8. PubMed ID: 16494652
[TBL] [Abstract][Full Text] [Related]
37. Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia.
Tiong HY; Tibung MJ; Macalalag M; Li MK; Consigliere D
Urol Int; 2009; 83(1):44-8. PubMed ID: 19641358
[TBL] [Abstract][Full Text] [Related]
38. Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group.
Buzelin JM; Hebert M; Blondin P
Br J Urol; 1993 Dec; 72(6):922-7. PubMed ID: 7508331
[TBL] [Abstract][Full Text] [Related]
39. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
Roehrborn CG
BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of a prolonged-release formulation of alfuzosin 10 mg once daily in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Kongkanand A; Chodchoy V; Lojanapiwat B; Pumpaisanchai S; Ratana-Olarn K; Sae-Tang P; Taweemonkongsap T
J Med Assoc Thai; 2009 Jul; 92(7):969-78. PubMed ID: 19626818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
